Arcellx Inc (NASDAQ: ACLX) introduced that new medical knowledge from its Section 1 research of CART-ddBCMA in sufferers with relapsed or refractory a number of myeloma shall be offered on the sixty fifth American Society of Hematology (ASH).
The information within the ASH summary revealed right now is from a June 2, 2023 knowledge lower and can embody new knowledge with a median follow-up of 26.5 months.
As detailed within the summary, 38 sufferers had been evaluable for efficacy and security evaluation, primarily based on a median follow-up of twenty-two months following remedy.
Associated: Analysts Keep Bullish On Arcellx’s CART-ddBCMA’s Lengthy-term Therapeutic Potential.
These evaluable sufferers comprised the dose escalation cohorts for the primary dose degree (100 (+/- 20) million CAR+ T cells, n=6) and the second dose degree (300 (+/- 20) million CAR+ T cells, n=6), and a dose enlargement cohort at 100 (+/- 20) million CAR+ T cells (n=26).
Of the 38 evaluable sufferers with a median follow-up of twenty-two months, a 100% total response charge (ORR) was achieved in all sufferers.
29 of 38 evaluable sufferers achieved a whole response (CR) or a stringent full response (sCR) (> CR charge, 76%)
35 sufferers achieved an excellent partial response or larger (>VGPR charge, 92%)
The median period of response, progression-free survival (PFS), and total survival weren’t reached on the time of the June 2, 2023 knowledge lower as a result of 25 of 38 (66%) evaluable sufferers had ongoing responses.
The Kaplan-Meier methodology estimated PFS charges for six, 12, and 18 months had been 92%, 74%, and 67% respectively.
Sturdy responses had been additionally noticed in sufferers with high-risk options and high-risk cytogenetics.
Value Motion: ACLX shares are up 17.30% at $40.35 on the final verify Thursday.
Supply Hyperlink : metechyou.com
